Samjin anti-viral drug appointed to NIH/NIAID project.

Published: 2005-10-26 06:58:00

Updated: 2005-10-26 06:58:00

An anti-viral compound, a pyrimidindione derivative, developed by Samjin has been appointed as one of the topical anti-viral drug R&D projects for the prevention of HIV infections by the U. S. NIH (NIH/NIAID).

It is effective against HIV-1 and HIV-2 virus, showing quite a high level (at 500 th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK